Business
ViaDerma, Inc. Starts Phase II of MMJ and Recreational Testing in Canada, also is Now Fast Tracking its Topical Antibiotic with the BFAD (Bureau of Food and Drugs) in Philippines for Approval of its FDA Registered Product
ViaDerma, Inc. Starts Phase II of MMJ and Recreational Testing in Canada, also is Now Fast Tracking its Topical Antibiotic with the BFAD (Bureau of Food and Drugs) in Philippines for Approval of its FDA Registered Product.
About this update from Viaderma, Inc.
[{"type":"text","content":"\nViaDerma, Inc. Starts Phase II of MMJ and Recreational Testing in Canada, also is Now Fast Tracking its Topical Antibiotic with the BFAD (Bureau of Food and Drugs) in Philippines for Approval of its FDA Registered Product\n\nViaDerma, Inc. Starts Phase II of MMJ and Recreational Testing in Canada, also is Now Fast Tracking its Topical Antibiotic with the BFAD (Bureau of Food and Drugs) in Philippines for Approval of its FDA Registered Product\n\n\nViaDerma and its Partners in the Philippines Have Had Quick Initial Results and Look to Expand Initial Test Studies and have Partnered with Major Hospitals and Its Main Distributor in a Move to Fast track its FDA Registered Topical Antibiotic \n\n LOS ANGELES, CA--(Marketwired - July 27, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, announced today that the Company has now started Phase II of the testing for Medical & Recreational Marijuana in Canada. The Company passed Phase I testing for efficacy and Phase II is now for the combination and calculation of the formulas for both CBD's and THC delivery using the Company's proprietary delivery solution. Secondly, the Company is now working with its main Distributor and major Hospitals, in the Philippines, in a move to \"Fast Track\" its approval for its topical antibiotic and expand its testing. The goal is to use the facilities of the major Hospitals to gain \"Fast Track\" approval by the BFAD, the Philippines equivalent to the Unites States Food and Drug Administration. The initial testing has already shown promising results and the expanded \"Clinical Trials\" of its topical antibiotic continues to show results not seen before in the region. The product's positive and quick results, continue to create excitement by doctors and distributors throughout the country. The Distributors are also interested in ViaDerma's several follow-on products, using ViaDerma's proprietary solution, for which the Company is expecting additional FDA registration numbers throughout the remainder of 2017. The Company's President, Dr. Christopher Otiko said, \"The studies for several of our products continue to show positive results and the Company's credibility continues to rise. The patients in our on-going testing have shown positive results not seen before. The increased intere...